Taligen gets $10M cash injection for rare disease programs

Taligen Therapeutics has hit another milestone on its journey in search of new therapies for a broad array of inflammatory and immune diseases. The Cambridge, MA-based developer has snagged a $10 million tranche in its $65 million Series B, earmarking much of the money for early clinical stage development work for its lead candidate - TT30. Taligen set out to prove its drug platform could regulate the "complement system," a pathway in the human immune system. And it has initially zeroed in on...